AOD9604 and Safety Pharmacology Research A conventional Ames test showed no significant mutation rate increase for AOD9604 at up to 2,000 g/plate, with no clastogenic effects observed in CHO-cell chromosome aberration assays
human bioavailability is unknown Subcutaneous injection Human subcutaneous bioavailability and pharmacokinetics are unknown Factor Convenience Oral capsules No mixing or syringe math Subcutaneous injection Requires reconstitution, sterile supplies, and injection-site planning Factor Evidence limits Oral capsules No controlled human dose, benefit, or safety trial Subcutaneous injection No controlled human dose, benefit, or safety trial Factor Can the amounts be treated as equal
While they both could aid in shedding a few pounds, each has their own distinct mechanism of action
Before continuing, please confirm the following: By continuing you agree to our Terms of Service, Research Use Only Policy, Waiver & Release, and Privacy Policy
All products and medications are manufactured and distributed by independent, third-party vendor pharmacies and are routinely inspected by both state and federal agencies for safety and efficacy